<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126046</url>
  </required_header>
  <id_info>
    <org_study_id>NFTM20130101</org_study_id>
    <nct_id>NCT02126046</nct_id>
  </id_info>
  <brief_title>Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <brief_summary>
    <textblock>
      Allo-hematopoietic stem cell transplantation(HSCT) is the only way to cure β-thalassemia
      major at present. To expand donor pool，we developed a haplo-identical HSCT (Hi-HSCT)
      platform. But in prior Hi-HSCT using high dose post-transplant Cyclophosphamide in patients
      with leukemia, cytopenia post-transplant often developed, which was considered as a symptom
      of GVHD. Therefore, the investigators add unrelated umbilical cord blood (UCB) to the
      Hi-HSCT. It has reported that, as third-party cells, UCB will reduce GVHD.The purpose of this
      study is to determine whether unrelated UCB following Hi-HSCT can improve outcomes of Hi-HSCT
      in patients with β-thalassemia major.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival（OS）</measure>
    <time_frame>12 months</time_frame>
    <description>the measure is a composite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TM-free survival（TFS）</measure>
    <time_frame>12 months</time_frame>
    <description>the measure is a composite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant Related Martality (TRM)</measure>
    <time_frame>12 months</time_frame>
    <description>the measure is a composite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary or Secondary Graft Rejection (GR)</measure>
    <time_frame>12 months</time_frame>
    <description>the measure is a composite</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The cumulative incidences of acute graft-versus-host disease（GVHD）</measure>
    <time_frame>12 months</time_frame>
    <description>the measure is a composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative incidences of chronic graft vesus host disease (cGVHD)</measure>
    <time_frame>12 months</time_frame>
    <description>the measure is a composite</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>Hi-HSC-CBT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>unrelated CB following haplo-identical hematopoietic stem cells transplantation</intervention_name>
    <arm_group_label>Hi-HSC-CBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  β-thalassemia major

          -  &lt; 18 year old

          -  Unrelated umbilical cord blood following Haplo-identical HSCT

        Exclusion Criteria:

          -  ≥ 18 year old

          -  HLA- matched related donors

          -  Unrelated donor transplants

          -  Unrelated umbilical cord blood transplants

          -  Severe iron overload in heart by T2*
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunfu Li, professor</last_name>
    <phone>+86 20 61641921</phone>
    <email>chunfugzcn@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhiyong Peng, Doctor</last_name>
    <phone>+86 20 61641925</phone>
    <email>pengzhiyong8@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of paediatrics，Nangfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunfu Li, professor</last_name>
      <phone>+86 20-61641921</phone>
      <email>chunfugzcn@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2014</study_first_submitted>
  <study_first_submitted_qc>April 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <last_update_submitted>April 15, 2015</last_update_submitted>
  <last_update_submitted_qc>April 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Chunfu Li</investigator_full_name>
    <investigator_title>Director and professor</investigator_title>
  </responsible_party>
  <keyword>Cord Blood Transplant</keyword>
  <keyword>Haploidentical HSCT</keyword>
  <keyword>Thalassemia major</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

